Cycuria, Therapeutics

Cycuria Therapeutics Launches with the Formation of a Distinguished Advisory Board and Significant Public Grant Funding

Veröffentlicht: 07.08.2025 um 18:08 Uhr, prnewswire.co.uk

Cycuria Therapeutics Germany United Kingdom United States of America Switzerland Austria France

Cycuria aims to revolutionise treatment of hard-to-treat blood cancers with a first-in-class protein-based therapeutic approach specifically targeting both tumour cells and tumour stem cellsAdvisory Board unites distinguished experts in corporate strategy, clinical haemato-oncology, protein engineering and early-stage drug discovery and developmentGrant funding secured from innovation-supporting Austrian government bodies FFG and AWSView original content:https://www.prnewswire.co.uk/news-releases/cycuria-therapeutics-launches-with-the-formation-of-a-distinguished-advisory-board-and-significant-public-grant-funding-302438596.html

en | boerse | 67934989 |